title: Treatment of agarose-agarose RENCA macrobeads with docetaxel selects for OCT4(+) cells with tumor-initiating capability.
abstract: The cancer stem cell (CSC) theory depicts such cells as having the capacity to produce both identical CSCs (symmetrical division) and tumor-amplifying daughter cells (asymmetric division). CSCs are thought to reside in niches similar to those of normal stem cells as described for neural, intestinal, and epidermal tissue, are resistant to chemotherapy, and are responsible for tumor recurrence. We recently described the niche-like nature of mouse renal adenocarcinoma (RENCA) cells following encapsulation in agarose macrobeads. In this paper we tested the hypothesis that encapsulated RENCA colonies function as an in vitro model of a CSC niche and that the majority of cells would undergo chemotherapy-induced death, followed by tumor recurrence. After exposure to docetaxel (5 µg/ml), 50% of cells were lost one week post-treatment while only one or two cells remained in each colony by 6 weeks. Surviving cells expressed OCT4 and reformed tumors at 16 weeks post-treatment. Docetaxel-resistant cells also grew as monolayers in cell culture (16-17 weeks post-exposure) or as primary tumors following transplantation to Balb/c mice (6 of 10 mice) or NOD.CB17-Prkdc(scid)/J mice (9 of 9 mice; 10 weeks post-transplantation or 28 weeks post-exposure). These data support the hypothesis that a rare subpopulation of OCT4(+) cells are resistant to docetaxel and these cells are sufficient for tumor recurrence. The reported methodology can be used to obtain purified populations of tumor-initiating cells, to screen for anti-tumor-initiating cell agents, and to investigate the in vitro correlate of a CSC niche, especially as it relates to chemo-resistance and tumor recurrence.
authors.affiliation: The Rogosin Institute; New York, NY USA; The Rogosin Institute-Xenia Division; Xenia, OH USA.
authors.forename: Lawrence S
authors.initials: LS
authors.lastname: Gazda
authors.affiliation: The Rogosin Institute-Xenia Division; Xenia, OH USA.
authors.forename: Prithy C
authors.initials: PC
authors.lastname: Martis
authors.affiliation: The Rogosin Institute-Xenia Division; Xenia, OH USA.
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Laramore
authors.affiliation: The Rogosin Institute-Xenia Division; Xenia, OH USA.
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Bautista
authors.affiliation: The Rogosin Institute-Xenia Division; Xenia, OH USA.
authors.forename: Atira
authors.initials: A
authors.lastname: Dudley
authors.affiliation: The Rogosin Institute-Xenia Division; Xenia, OH USA.
authors.forename: Horatiu V
authors.initials: HV
authors.lastname: Vinerean
authors.affiliation: The Rogosin Institute; New York, NY USA; Department of Surgery; Weill Medical College of Cornell University; New York, NY USA; NewYork-Presbyterian Hospital; New York, NY USA.
authors.forename: Barry H
authors.initials: BH
authors.lastname: Smith
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D045744:Cell Line, Tumor; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D008807:Mice, Inbred BALB C; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D050814:Octamer Transcription Factor-3 / Q000378:metabolism*; D017239:Paclitaxel / Q000494:pharmacology; D012685:Sepharose; D043823:Taxoids / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D050814:Octamer Transcription Factor-3; C494173:POU5F1 protein, human; D043823:Taxoids; D000077143:Docetaxel; D012685:Sepharose; D017239:Paclitaxel
keywords: OCT4; RENCA; encapsulation; macrobeads; tumor-initiating cells
references.citation: Nature. 2012 Aug 23;488(7412):522-6
references.pmid: 22854781
references.citation: Breast Cancer Res. 2011 Sep 27;13(5):R94
references.pmid: 21952072
references.citation: Nature. 1990 Jun 21;345(6277):686-92
references.pmid: 1972777
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3871-6
references.pmid: 17360445
references.citation: Cancer Res. 2009 Mar 1;69(5):1776-81
references.pmid: 19208848
references.citation: Nature. 1994 Feb 17;367(6464):645-8
references.pmid: 7509044
references.citation: Cancer Res. 2011 Feb 1;71(3):634-9
references.pmid: 21266356
references.citation: Cancer Res. 2011 Feb 1;71(3):725-35
references.pmid: 21266362
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2010 Feb;30(1):81-4
references.pmid: 20155460
references.citation: J Oncol. 2011;2011:941876
references.pmid: 20981352
references.citation: Nature. 2007 Jul 19;448(7151):313-7
references.pmid: 17554338
references.citation: J Cell Biochem. 2011 Jan;112(1):1-9
references.pmid: 20626029
references.citation: Clin Cancer Res. 2010 Jun 15;16(12):3121-9
references.pmid: 20530700
references.citation: Nature. 2011 Jan 20;469(7330):314-22
references.pmid: 21248838
references.citation: Nature. 2008 Jan 10;451(7175):141-6
references.pmid: 18157115
references.citation: Biochim Biophys Acta. 2010 Jan;1805(1):105-17
references.pmid: 19931353
references.citation: Br J Cancer. 2010 Aug 10;103(4):439-45
references.pmid: 20664590
references.citation: J Clin Oncol. 2008 Jun 10;26(17):2839-45
references.pmid: 18539962
references.citation: Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):593-602
references.pmid: 20705681
references.citation: Cell. 2005 May 6;121(3):465-77
references.pmid: 15882627
references.citation: Cancer Res. 2011 Feb 1;71(3):716-24
references.pmid: 21266363
references.citation: Stem Cells. 2008 Jan;26(1):30-4
references.pmid: 17932422
references.citation: PLoS One. 2012;7(2):e32287
references.pmid: 22359678
references.citation: Nat Rev Mol Cell Biol. 2008 Jan;9(1):11-21
references.pmid: 18097443
references.citation: Bioessays. 2009 Oct;31(10):1038-49
references.pmid: 19708024
references.citation: J Oncol. 2011;2011:
references.pmid: 20936110
references.citation: Cell. 1998 Oct 30;95(3):379-91
references.pmid: 9814708
references.citation: Cell. 2006 Aug 25;126(4):677-89
references.pmid: 16923388
references.citation: Nat Rev Cancer. 2007 Feb;7(2):139-47
references.pmid: 17218951
references.citation: Science. 2012 Aug 10;337(6095):730-5
references.pmid: 22855427
references.citation: Science. 2000 Oct 13;290(5490):328-30
references.pmid: 11030649
references.citation: PLoS One. 2008 Jul 09;3(7):e2637
references.pmid: 18612434
references.citation: Cancer Res. 2006 Oct 1;66(19):9339-44
references.pmid: 16990346
references.citation: Nature. 2001 Nov 1;414(6859):105-11
references.pmid: 11689955
references.citation: Nature. 2012 Aug 23;488(7412):527-30
references.pmid: 22854777
references.citation: Cancer Res. 2005 Jul 1;65(13):5506-11
references.pmid: 15994920
references.citation: Int J Cancer. 2011 Nov 15;129(10):2315-27
references.pmid: 21792897
references.citation: Genes Cancer. 2010 Sep;1(9):908-16
references.pmid: 21779471
references.citation: Hepatology. 2010 Aug;52(2):528-39
references.pmid: 20683952
references.citation: Expert Opin Ther Targets. 2007 Jul;11(7):915-27
references.pmid: 17614760
references.citation: J Clin Invest. 2011 Oct;121(10):3804-9
references.pmid: 21965337
references.citation: J Biomech. 2010 Jan 5;43(1):55-62
references.pmid: 19800626
references.citation: Cell Stem Cell. 2008 Jan 10;2(1):39-49
references.pmid: 18371420
references.citation: Science. 2007 Dec 21;318(5858):1917-20
references.pmid: 18029452